These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 2145219)
21. T cell activation by a bispecific anti-CD3/anti-major histocompatibility complex class I antibody. Roosnek E; Tunnacliffe A; Lanzavecchia A Eur J Immunol; 1990 Jun; 20(6):1393-6. PubMed ID: 2142461 [TBL] [Abstract][Full Text] [Related]
22. Activation of T cells by cross-linking an anti-CD3 antibody with a second anti-T cell antibody: mechanism and subset-specific activation. Walker C; Bettens F; Pichler WJ Eur J Immunol; 1987 Jun; 17(6):873-80. PubMed ID: 2439351 [TBL] [Abstract][Full Text] [Related]
23. Cloned helper T lymphocytes exposed to interleukin 2 become unresponsive to antigen and concanavalin A but not to calcium ionophore and phorbol ester. Otten G; Wilde DB; Prystowsky MB; Olshan JS; Rabin H; Henderson LE; Fitch FW Eur J Immunol; 1986 Mar; 16(3):217-25. PubMed ID: 2937640 [TBL] [Abstract][Full Text] [Related]
24. Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: costimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1. van Seventer GA; Newman W; Shimizu Y; Nutman TB; Tanaka Y; Horgan KJ; Gopal TV; Ennis E; O'Sullivan D; Grey H J Exp Med; 1991 Oct; 174(4):901-13. PubMed ID: 1717633 [TBL] [Abstract][Full Text] [Related]
25. Differences in the stimulating capacity of immobilized anti-CD3 monoclonal antibodies: variable dependence on interleukin-1 as a helper signal for T-cell activation. Verwilghen J; Baroja ML; Van Vaeck F; Van Damme J; Ceuppens JL Immunology; 1991 Feb; 72(2):269-76. PubMed ID: 1826671 [TBL] [Abstract][Full Text] [Related]
26. Modulatory effect of aggregating the CD3 molecular complex on T cell activation. Gur H; Wacholtz MC; Davis LS; Geppert TD; Lipsky PE Cell Immunol; 1992 Mar; 140(1):81-96. PubMed ID: 1531456 [TBL] [Abstract][Full Text] [Related]
27. Activation of resting T lymphocytes by anti-CD3 (T3) antibodies in the absence of monocytes. Tsoukas CD; Landgraf B; Bentin J; Valentine M; Lotz M; Vaughan JH; Carson DA J Immunol; 1985 Sep; 135(3):1719-23. PubMed ID: 3926881 [TBL] [Abstract][Full Text] [Related]
28. The required interaction between monocytes and peripheral blood T lymphocytes (T-PBL) upon activation via CD2 or CD3. Role of HLA class I molecules from accessory cells and the differential response of T-PBL subsets. Huet S; Boumsell L; Dausset J; Degos L; Bernard A Eur J Immunol; 1988 Aug; 18(8):1187-94. PubMed ID: 2901355 [TBL] [Abstract][Full Text] [Related]
29. Induction of interleukin 2 (IL 2) and interferon-gamma and enhancement of IL 2 receptor expression by a CD26 monoclonal antibody. Plana M; Viñas O; De la Calle-Martin O; Lozano F; Inglés-Esteve J; Romero M; Alberola-Ila J; Yagüe J; Vilella R; Vives J Eur J Immunol; 1991 Apr; 21(4):1085-8. PubMed ID: 1673434 [TBL] [Abstract][Full Text] [Related]
30. Activation via the CD3 and CD16 pathway mediates interleukin-2-dependent autocrine proliferation of granular lymphocytes in patients with granular lymphocyte proliferative disorders. Hoshino S; Oshimi K; Teramura M; Mizoguchi H Blood; 1991 Dec; 78(12):3232-40. PubMed ID: 1835892 [TBL] [Abstract][Full Text] [Related]
31. The anti-T cell monoclonal antibody 9.3 (anti-CD28) provides a helper signal and bypasses the need for accessory cells in T cell activation with immobilized anti-CD3 and mitogens. Baroja ML; Lorre K; Van Vaeck F; Ceuppens JL Cell Immunol; 1989 Apr; 120(1):205-17. PubMed ID: 2539266 [TBL] [Abstract][Full Text] [Related]
32. T cell activation via the T cell receptor: a comparison between WT31 (defining alpha/beta TcR)-induced and anti-CD3-induced activation of human T lymphocytes. Gupta S; Shimizu M; Ohira K; Vayuvegula B Cell Immunol; 1991 Jan; 132(1):26-44. PubMed ID: 1829655 [TBL] [Abstract][Full Text] [Related]
33. T cell activation by cross-linking anti-CD3 antibodies with second anti-T cell antibodies: dual antibody cross-linking mimics physical monocyte interaction. Walker C; Bettens F; Pichler WJ Eur J Immunol; 1987 Nov; 17(11):1611-8. PubMed ID: 2960544 [TBL] [Abstract][Full Text] [Related]
34. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets. Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457 [TBL] [Abstract][Full Text] [Related]
35. CD3 pathway of T-cell activation. II. Role of HLA-class I molecules in early events. Schwab R; Weksler ME; Russo C Cell Immunol; 1988 Sep; 115(2):310-24. PubMed ID: 2457448 [TBL] [Abstract][Full Text] [Related]
36. The cascading, interrelated roles of interleukin-1, interleukin-2, and interleukin-6 in murine anti-CD3-driven T cell proliferation. Pankewycz OG; Yui M; Kelley VE; Strom TB Clin Immunol Immunopathol; 1990 Apr; 55(1):67-85. PubMed ID: 2137741 [TBL] [Abstract][Full Text] [Related]
37. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817 [TBL] [Abstract][Full Text] [Related]